Vor Biopharma (VOR) Enterprise Value (2020 - 2026)
Vor Biopharma (VOR) posted quarterly Enterprise Value of -$491.5 million for Q1 2026, down 718.73% year-over-year from $79.4 million in Q1 2025, and down 7.98% quarter-over-quarter from -$455.2 million in Q4 2025.
Vor Biopharma (VOR) Enterprise Value (2020 - 2026) Analysis & Trends
Vor Biopharma (VOR) has reported Enterprise Value for 7 consecutive years, with -$491.5 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Enterprise Value fell 718.73% year-over-year to -$491.5 million; the TTM figure through Mar 2026 stood at -$491.5 million (down 718.73% YoY), while the FY2025 annual figure was -$455.2 million, down 395.19% from the prior year.
- Enterprise Value retreated to -$491.5 million in Q1 2026 per VOR's latest filing, from -$455.2 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$60.0 million in Q1 2025 and bottomed at -$491.5 million in Q1 2026.
- Historically, Enterprise Value has averaged -$183.5 million across 5 years, with a median of -$160.1 million in 2023.
- Annual changes were most pronounced in 2024 — Enterprise Value soared 60.77% — and 2026, when it tumbled 718.73%.
- Vor Biopharma's Enterprise Value stood at -$230.2 million in 2022, then surged by 40.42% to -$137.2 million in 2023, then surged by 32.99% to -$91.9 million in 2024, then sank by 395.19% to -$455.2 million in 2025, then dropped by 7.98% to -$491.5 million in 2026.
- Business Quant data shows VOR's Enterprise Value at -$491.5 million in Q1 2026, -$455.2 million in Q4 2025, and -$170.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | -5.18 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -3.94 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -8.46 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 2.12 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -3.31 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.16 Bn |
| 10 | Vor Biopharma | 1.36 Bn | 1.36 Bn | - | -466.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -466.13 Mn |
| Mar 31, 2026 | -491.53 Mn |
| Dec 31, 2025 | -455.21 Mn |
| Sep 30, 2025 | -170.46 Mn |
| Jun 30, 2025 | -200.57 Mn |
| Mar 31, 2025 | -60.04 Mn |
| Dec 31, 2024 | -91.93 Mn |
| Sep 30, 2024 | -62.81 Mn |
| Jun 30, 2024 | -85.94 Mn |
| Mar 31, 2024 | -107.48 Mn |
| Dec 31, 2023 | -137.18 Mn |
| Sep 30, 2023 | -160.10 Mn |
| Jun 30, 2023 | -186.90 Mn |
| Mar 31, 2023 | -210.20 Mn |
| Dec 31, 2022 | -230.25 Mn |
| Sep 30, 2022 | -136.07 Mn |
| Jun 30, 2022 | -151.09 Mn |
| Mar 31, 2022 | -181.62 Mn |
| Dec 31, 2021 | -207.47 Mn |
| Sep 30, 2021 | -225.97 Mn |